Therapeutic | Target | Format and engineering | Disease area | Status (selected trials) |
MDX-447 | EGFRxFcγRI | Bispecific antibody with activated monocytes | Recurrent glioblastoma | Completed (NCT00005813) |
AMG596 (Amgen) | EGFRvIIIxCD3 | Bispecific T-cell engager±pembrolizumab (anti-PD-1) | New and recurrent glioblastoma | Phase I (NCT03296696) |
BRiTE | EGFRvIIIxCD3 | Bispecific T-cell engager | New and recurrent glioblastoma | Phase I (NCT04903795) |
EGFR BAT | EGFRxCD3 | EGFR biarmed activated T cells (cetuximab and OKT3) with SOC (TMZ/RT) | New glioblastoma | Phase I (NCT03344250) |
BRiTE, brain bispecific T-cell engager; EGFR, epidermal growth factor receptor; EGFRvIII, epidermal growth factor receptor variant III.